Pascal Biosciences
  • Company
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact
Skip to content
Home / News / Page 2

News

28Dec 2018

Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones

  • Dec 28, 2018
  • Press Releases

- 2018 pipeline expansion includes lead cannabinoid-based cancer therapeutic - Clinical trial in glioblastoma to begin in 2019 VANCOUVER, British Columbia and SEATTLE, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development…

Read More

11Dec 2018

Pascal Biosciences Announces Year-End Investor Update Webcast

  • Dec 11, 2018
  • Press Releases

Advancement of Cannabinoid Cancer Programs and Corporate Review to be Presented Scheduled for Dec. 17, 2018 at 1:30 p.m. Pacific VANCOUVER, British Columbia and SEATTLE, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug…

Read More

28Nov 2018

Pascal Biosciences Expands Leadership Team to Support Strategic Advancement of Its Cannabinoid Based Programs

  • Nov 28, 2018
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, November 28, 2018 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the strengthening of its leadership team with the appointments of seasoned executives in therapeutic…

Read More

10Nov 2018

Pascal Biosciences CEO interview on Canada Pot Talks 107.7 Pulse FM (minute 46)

  • Nov 10, 2018
  • In the News

Listen to an interview with CEO Patrick Gray on Canada Pot Talks. Canada Pot Talks - November 10th 2018

Read More

8Nov 2018

CFN's exclusive Interview with Pascal Biosciences

  • Nov 8, 2018
  • In the News

CEO Patrick Gray sat down with CFN Media for an exclusive interview. Read the full interview here.  

Read More

5Nov 2018

Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells

  • Nov 5, 2018
  • Press Releases

VANCOUVER, British Columbia and SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today announced the peer reviewed publication and upcoming presentation of their recently licensed cannabinoid-derived drug program for…

Read More

30Oct 2018

Pascal Biosciences and the University of Washington Enter Into Exclusive License Agreement to Develop Cannabinoid-based Medicine for Cancer

  • Oct 30, 2018
  • Press Releases

Program Developed in Lab of Renowned Cannabis Researcher Dr. Nephi Stella Lead Candidate for Glioblastoma to Begin Clinical Testing in 2019 VANCOUVER, B.C. and SEATTLE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a…

Read More

16Jul 2018

Pascal Biosciences appoints Julie M. Eastland, accomplished financial executive, to Board of Directors

  • Jul 16, 2018
  • Press Releases

VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the appointment of Julie M. Eastland to the Board of Directors, effective immediately. Ms. Eastland is a…

Read More

18Jun 2018

Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration

  • Jun 18, 2018
  • Press Releases

VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX-V:PAS) (Pascal), is pleased to announce significant progress in its cannabinoid based research and development program with the University of British Columbia (UBC). Pascal has been licensed by…

Read More

21Feb 2018

Pascal Biosciences Identifies Molecules in Cannabis That Stimulate the Immune System to Destroy Tumor Cells

  • Feb 21, 2018
  • Press Releases

VANCOUVER, BRITISH COLUMBIA and SEATTLE, WASHINGTON, February 21, 2018 - Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today announced the Company has discovered certain cannabinoids that enhance the immunogenicity of tumor cells, rendering them more susceptible to recognition by the immune system.…

Read More

Page Navigation

  • Previous
  • 1
  • 2
  • 3
  • Next

Recent Posts

  • Pascal Biosciences and Y-Biologics Announce Research Collaboration for Development of a Bispecific Antibody for Leukemia
  • Pascal Biosciences Discovers Cannabinoids Activate the Major Histocompatibility Complex to Aid Cancer Treatment
  • Pascal Biosciences to Present at International Cannabinoid Derived Pharmaceuticals Summit
  • Pascal Biosciences to Present at 2019 BIO International Convention
  • Pascal Biosciences Announces Formation of Clinical Advisory Board

Categories

  • In the News
  • Press Releases
  • Uncategorized

Archives

  • October 2019
  • September 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • July 2018
  • June 2018
  • February 2018
  • December 2017
  • September 2017
  • May 2017
  • March 2017
  • November 2016
  • October 2016
  • September 2016

About

Pascal Biosciences Inc. (TSX-V: PAS) is a biotechnology company focused on developing cannabinoid-based and targeted therapeutics to fight cancer.

Locations

USA

Fluke Hall, Suite 304
Box 352141
4000 Mason Road
Seattle, WA 98195-2141

Canada

280 7th Avenue East
Vancouver, BC V5T 0B4

Contact

Phone

206.221.3443

Email

info@pascalbiosciences.com

Investors

invest@pascalbiosciences.com

Partnering & Business Development

bd@pascalbiosciences.com

Let's Connect

  • Twitter
  • Linked
  • Home
  • Company
  • Programs
  • News
  • Investors
  • Contact
  • Disclaimer

© Copyright 2019 Pascal Biosciences Inc. All rights reserved.   Seattle Website Design by Jordan Crown Design

  • Company
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact

‹ › ×